Kronos Bio(KRON) - 2024 Q2 - Quarterly Results

Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update — First patient in platinum-resistant high-grade serous ovarian cancer cohort was dosed on optimized dose and schedule with istisociclib (KB-0742); expect data update in 1H 2025 — — KB-9558 IND-enabling studies for multiple myeloma remain on track to be completed in Q4 2024 — — Pipeline update includes an additional indication for KB-9558 in HPV-driven tumors and a separate p300 program focused on autoimmune indications — — $136.6 ...